Brief: Firebrick Pharma To File Appeal Seeking Immediate Approval Of Nasodine
28/02/2022 23:12
March 1 (Reuters) - Firebrick Pharma Ltd FRE.AX :
* FRE TO FILE APPEAL SEEKING IMMEDIATE APPROVAL OF
NASODINE-FRE.AX
* DECIDED TO FILE AN APPEAL AGAINST TGA'S INITIAL DECISION
NOT TO
APPROVE NASODINE NASAL SPRAY FOR SALE IN AUSTRALIA
Source text for Eikon: ID:nASX8Hgyzn
Further company coverage: FRE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement